Novavax (NVAX) news
Recent news
Novavax says partners got Nuvaxovid formulation approval
Novavax Inc. announced that its partners have received regulatory approval for the updated formulation of its Nuvaxovid™ COVID-19 vaccine, designed for the 2025–2026 season . The approval marks a key milestone in the company’s strategy to provide a protein-based alternative to mRNA vaccines in the…
AInvest Wire · 3d agoNovavax: Eligible for royalties on net sales in U.S., EU, Japan for 2026-2027 season
AInvest Wire · 3d agoU.S.-listed shares of biotech up 17.4%, Novavax rises 5.9%
U.S.-listed biotech shares rose 17.4% in recent trading, driven by renewed investor confidence in the sector and a broader market rally. Among the top performers was Novavax, Inc. (NVAX), whose shares climbed 5.9% following the release of its Q2 2026 financial results. The company reported total…
AInvest Wire · Aug 19, 2026Biotech ADRs rally 14%, while Novavax up 5.8%
AInvest Wire · Aug 19, 2026NVAX sees FY adj. total rev. $235M to $275M, saw $230M to $270M
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.